Moderna, racing to develop a vaccine for Covid-19, lost a key patent decision Thursday, one that could delay the company’s progress or force it to hand over a cut of profits.
The U.S. Patent and Trademark Office denied Moderna’s claim that a patent held by a rival company was invalid. The patent, which covers technology used to deliver messenger RNA treatments, is held by the Canadian firm Arbutus.
About the Author Reprints
This could be good news for Matinas Biopharma (MTNB) that has a superior liquid crystal nano delivery system that could potentially be used in place of the inferior LNP delivery system of Arbutus.
MTNB is up 20% today is very heavy volume.